4:07 pm Theravance announces positive results from a Phase 2 study of TD-9855 in patients With fibromyalgia; 5 mg dose did not meet statistical significance for the primary endpoint
View todays social media effects on THRX
View the latest stocks trending across Twitter. Click to view dashboard
See who Theravance is hiring next, click here to view
